Loading provider…
Loading provider…
Infectious Disease Physician in Philadelphia, PA
NPI: 1043247935Primary Practice Location
HOSPITAL OF UNIV OF PENNSYLVANIA
3400 Spruce St, Philadelphia, PA
Primary Employer
University of Penn-Medical Group
pathology.med.upenn.edu
HQ Phone
Get MD Emily's Phone Numberphone_androidMobile
Get MD Emily's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardPA State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 52 | 223 |
| 2 | 99223Initial hospital inpatient care, typically 70 minutes per day | 33 | 35 |
| 3 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 27 | 68 |
| 4 | 99215Established patient office or other outpatient, visit typically 40 minutes | 25 | 40 |
| 5 | 99214Established patient office or other outpatient visit, 30-39 minutes | 22 | 25 |
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation.
Authors: Randi Leavitt, David Snydman, Mark Dinubile, Roy Chemaly, Francisco Marty, Michael Boeckh, Kathleen Mullane, Sanjeet Dadwal
Publication Date: 2017-12-07
Just Say No: Stemming the Tide of Antibiotic Overprescription.
Authors: @ValidYN, LastName, ForeName, Initials, AffiliationInfo
Journal: Am J Transplant
Publication Date: 2016-06-20
A phase I trial of cyclosporine for hospitalized patients with COVID-19.
Authors: Pablo Tebas, Carl June, Ian Frank, Hooman Noorchashm, Elizabeth Hexner
Journal: JCI Insight
Publication Date: 2022-06-08
Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators: PPD Development, LP, Johns Hopkins University
Intervention / Treatment: BIOLOGICAL: Pfizer-BioNTech COVID-19 Vaccine 2023-2024, BIOLOGICAL: Moderna COVID-19 Vaccine 2023-2024, DRUG: SOC IS Regimen, DRUG: SOC IS Reduction
Lead Sponsor: Johns Hopkins University
Collaborators: National Institute of Allergy and Infectious Diseases (NIAID)
Intervention / Treatment: OTHER: HIV D+/R+
Lead Sponsor: Regeneron Pharmaceuticals
Intervention / Treatment: DRUG: Placebo, DRUG: casirivimab+imdevimab